Vaccine｜Moderna sets up an office in Hong Kong Innovation and Technology Bureau: Moderna explores setting up production lines in Hong Kong

Multinational pharmaceutical and biotechnology company Moderna (Moderna) established an office in Hong Kong. Sun Dong, Director of the Bureau of Innovation, Technology and Industry, today (9th), together with staff from the Investment Promotion Agency and the Science and Technology Park Company, and Patrick, Senior Vice President of Moderna Bergstedt and his Asian team met.

The bureau quoted Moderna as saying that it would consider developing new vaccines in Hong Kong, as well as researching the application of mRNA technology in tumors and immunology, rare diseases and autoimmune diseases, and exploring the possibility of setting up production lines in Hong Kong .

The Bureau of Innovation, Technology and Industry stated that during the meeting, Director Sun Dong and the Moderna team had in-depth discussions on how to further expand their business in Hong Kong, including jointly establishing a global industry-university-research collaborative innovation platform.

Moderna is one of the companies that has produced a new crown vaccine.

The Bureau pointed out that Hong Kong has a solid foundation in biotechnology research and development. This year's "Policy Address" mentioned that it will focus on attracting outstanding enterprises and talents in technology industries with competitive advantages and strategic significance, including life and health technology, to settle in Hong Kong.

The Bureau of Innovation, Technology and Industry will work with the soon-to-be-established "Office for the Introduction of Key Enterprises" to actively promote relevant work, promote the development of Hong Kong's technology industry, improve the industry-university-research ecosystem as soon as possible, and build Hong Kong into an international innovation and technology center with global influence .

Sun Dong (fourth from left), Secretary for Innovation, Technology and Industry, met with Patrick Bergstedt (fifth from left), Senior Vice President of Moderna, and his Asian team today.

(Facebook photo of the Bureau of Innovation, Technology and Industry)

New Crown Vaccine︱Pfizer and BioNTech counter-sued Moderna's mRNA technology patent invalid British media: Moderna refused to provide China with mRNA technology sales negotiations in China broke down New Coronary Pneumonia︱The US FDA gave the green light to Pfizer's new version of Moderna's vaccine booster Fubitai Vaccine｜Modna Sues Pfizer BioNTech for Plagiarizing mRNA Patent Technology Epidemic｜The UK will provide the public with the Omicron bivalent Moderna vaccine from September 5. The UK approves the use of Moderna’s Omicron bivalent vaccine May consider purchasing